NSABPB40_3A | R Documentation |
Kaplan-Meier digitized data from NSABPB40, figure 3A (PMID 26272770). A reported sample size of 1,206 for a primary endpoint of pCR in breast cancer.
NSABPB40_3A
A data frame of 1,184 observations and 3 variables:
time | event time (in years) | |
event | DFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (bev, no_bev) | |
Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 2015; 16: 1037–48.
summary(NSABPB40_3A)
kmplot(NSABPB40_3A)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.